- Conditions
- Oligoprogressive Renal Cell Carcinoma
- Interventions
- Stereotactic ablative body radiation (SABR)
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 2,386
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Romidepsin
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 45
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 35 more
- Conditions
- Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
- Interventions
- Biospecimen Collection, Computed Tomography, Cyclophosphamide, Doxorubicin Hydrochloride, Echocardiography Test, Multigated Acquisition Scan, Pirtobrutinib, Positron Emission Tomography, Prednisone, Rituximab, Rituximab and Hyaluronidase Human, Survey Administration, Vincristine
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2036
- U.S. locations
- 62
- States / cities
- Irvine, California • Laguna Hills, California • Orange, California + 48 more
- Conditions
- Multiple Myeloma
- Interventions
- CART-19 T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Leukemia, Lymphoma
- Interventions
- biologic sample preservation procedure
- Other
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 0 Years to 120 Years
- Enrollment
- 1,873 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 214
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Aurora, Colorado + 156 more
- Conditions
- Retrospective Study, Glioma, Brain Neoplasms
- Interventions
- 18F(FET)PET
- Diagnostic Test
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
- Industry
- Eligibility
- Not listed
- Enrollment
- 253 participants
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 45 Years to 130 Years · Female only
- Enrollment
- 736 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2026
- U.S. locations
- 14
- States / cities
- Casa Grande, Arizona • Fountain Valley, California • New Britain, Connecticut + 11 more
- Conditions
- Motor Neuron Disease
- Interventions
- FLX-787-ODT (orally disintegrating tablet), Placebo ODT
- Drug
- Lead sponsor
- Flex Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more
- Conditions
- Relapsing-Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- natalizumab, standard of care
- Drug · Other
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 9 more
- Conditions
- Lung Carcinoma
- Interventions
- Accelerometry, Aerobic Exercise, Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Physical Performance Testing, Respiratory Muscle Training, Supportive Care, Survey Administration
- Procedure · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Presbyopia
- Interventions
- Multifocal soft contact lenses, Progressive addition lens spectacles
- Device · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 38 Years to 58 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- L-alanosine
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Baltimore, Maryland • Boston, Massachusetts + 2 more
- Conditions
- Head and Neck Cancer, Islet Cell Tumor, Metastatic Cancer, Pheochromocytoma
- Interventions
- octreotide acetate, yttrium Y 90 resin microspheres
- Drug · Radiation
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Trauma, Psychological
- Interventions
- PC-based Flash, EMDR-based Flash
- Behavioral
- Lead sponsor
- Trauma Institute & Child Trauma Institute
- Other
- Eligibility
- Not listed
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Northampton, Massachusetts
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- MOVES
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- PML, AIDS
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2005
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more
- Conditions
- Diffuse Intrinsic Pontine Glioma
- Interventions
- Radiation Therapy, Temsirolimus, Vorinostat
- Radiation · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 7 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Frontotemporal Dementia, FTD, FTD-GRN, Dementia, Frontotemporal
- Interventions
- Intrathalamic AAV.PGRN administration, Intrathalamic AVB-101
- Procedure · Genetic
- Lead sponsor
- AviadoBio Ltd
- Industry
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 3
- States / cities
- Columbus, Ohio • Nashville, Tennessee • Houston, Texas
- Conditions
- Recurrent High-Grade Gliomas, Progressive Low-Grade Gliomas, Malignant Gliomas
- Interventions
- Steroids, ZD6474
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Stroke, Ischemic, Chronic Stroke
- Interventions
- Non-invasive Electrical Spinal Cord Stimulation, Activity Based Rehabilitation
- Device · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Solid Tumors, Lymphoma
- Interventions
- ASTX660
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 31
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 23 more
- Conditions
- Advanced Solid Tumors
- Interventions
- PF-03758309
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Aurora, Colorado
- Conditions
- Leukemia, T-cell Prolymphocytic Leukemia (T-PLL), Cancer
- Interventions
- Venetoclax, Ibrutinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Rochester, Minnesota • Houston, Texas
- Conditions
- Solid Cancer
- Interventions
- Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
- Biological
- Lead sponsor
- Oncovir, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Chevy Chase, Maryland • Easton, Maryland • New York, New York